The new combined business will be called Viatris, and its debut is expected to be Nov. 16.
Mylan and Pfizer first announced their plans for a merger in July 2019 and said the new company would be a global pharmaceutical giant producing both generic and brand-name drugs. They said the new company will sell well-known branded drugs such as Mylan’ EpiPen and Pfizer’s Viagra and could generate up to $20 billion per year.
In March, the companies said they’d push back the merger until the second half of this year due to unexpected delays in getting regulatory approval caused by the COVID-19 pandemic.
More articles on pharmacy:
Ascension launches pharmacy services business Ascension Rx
Virginia pharmacist gets 2 years in prison for prescription drug scheme
AstraZeneca, Pfizer begin accelerated review for COVID-19 vaccines in UK
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
